Chat Rheum: Elevating SDM Conversations in RA

This interactive CME workshop sought to uncover the impact of shared decision making (SDM) on optimizing treatment decisions to achieve desired treatment targets in patients with rheumatoid arthritis (RA). Two fast-paced presentations spotlighted the strategy around SDM, including techniques to increase patient engagement and translating clinical trial evidence into good patient decisions. Next, leading faculty joined by a patient-actor staged patient-provider communication inspired by real-life scenarios. Attendees also had the option to enhance their own skills through a guided SDM practice exercise. The activity concluded with a roundtable discussion on patient-centered, team-based RA care, including time for Q&A. Throughout the workshop, participants were invited to interact verbally or via iPad® as well as explore decision aids and other provided educational resources.

Date: October 24, 2018

Venue: Marriott Marquis Chicago, Great Lakes Ballroom E/F, Chicago, Illinois

Review activity content under the Materials button (below).



Richard Martin, MD, MA

Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
East Lansing, Michigan

Sheetal Desai, MD, MSEd

Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California

Linda Grinnell-Merrick, MS, NP-BC

Nurse Practitioner,
Division of Allergy, Immunology, and Rheumatology
University of Rochester Medical Center
Clinical Associate, University of Rochester School of Nursing
President of The Rheumatology Nurses Society
Rochester, New York

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

Utilize best available evidence for choosing and adjusting DMARD therapy to achieve desired treatment targets in patients with rheumatoid arthritis

Effectively engage a patient with rheumatoid arthritis to make a shared decision about intensifying their DMARD therapy to attain tighter disease control

Explore best practices for providing team-based care for patients with rheumatoid arthritis 

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Sydney Pate and Marianna Shershneva, MD, PhD

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Linda Grinnell-Merrick, MS, NP-BC, has been on an advisory board for: AbbVie, Novartis, Pfizer, and Horizon; she has participated in a speaker’s bureau for: AbbVie, Celgene, Novartis, Janssen; she has also contracted research for Novartis
  • Presenter: Sheetal Desai, MD, MSEd, has participated in a speaker’s bureau for Janssen Biotech
  • Presenter: Richard Martin, MD, MA, has provided educational consultation for AbbVie; he has contracted research for Lilly, AbbVie, Amgen, AstraZeneca, and BI

Activity Information

Target Audience
The target audience for this initiative was rheumatologists and members of their healthcare team. Other healthcare professionals who treat patients with RA may have also benefited from participation.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designated this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Content Review
The views and opinions expressed in this activity were those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

The content of this activity was independently peer reviewed by two peer physicians and a patient with RA. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity may have included reference to unlabeled or unapproved uses of drugs.

This activity is provided by Forefront Collaborative.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit

Not Enrolled
This course is currently closed